Table 5.

Studies of SRS as treatment for recurrent high-grade gliomas.

Study	N	Histological grade	Median dose (Gy)	Median volume (cm3)	Median post-SRS survival (months)	Prognostic factors
Chamberlain et al., 1994 [34]	15	IV	13.4	17	8	NR
Hall et al., 1995 [35]	25	III–IV	20	28	6.5	Age, KPS
Shrieve et al., 1995 [27]	86	IV	13	10.1	12	Age, volume
Larson et al., 1996 [31]	93	IV	16	6.5	16.4	Age, grade, KPS, focality, and volume
Kondziolka et al., 1997 [36]	42	III–IV	15.5	6.5	21	Grade, volume
Cho et al., 1999 [23]	46	III–IV	17	10	11	Age, grade, KPS, and volume
Ulm et al., 2005 [30]	33	III–IV	15	—	—	Location, RPA
Hsieh et al., 2005 [24]	26	IV	12	21.6	10	KPS
Mahajan et al., 2005 [37]	41	IV	—	4.7	11	None
Combs et al., 2005 [21]	32	IV	15	10	10	None
Kong et al., 2008 [13]	114	III–IV	16	10.6	26 (III)–13 (IV)	Histology, volume
Patel et al., 2009 [18]	26	IV	18	10.4	8.5	None
Biswas et al., 2009 [38]	18	IV	15	8.4	5.3	NR
Villavicencio et al., 2009 [25]	26	IV	20	7	7	Extent of surgery
Pouratian et al., 2009 [22]	26	IV	6	21.3	9.4	KPS, PTV margin
Torok et al., 2011 [39]	14	IV	24	6.97	10	NR
Maranzano et al., 2011 [40]	13	IV	17.3	5.3	11	Radiation dose
Cuneo et al., 2012 [29]	63	III/IV	15	4.8	11	Age, KPS, and bevacizumab
Park et al., 2012 [41]	11	IV	16	13.6	17.9	None
Skeie et al., 2012 [17]	51	IV	12.2	12.4	19 (from initial diagnosis)	None
Martínez-Carrillo 2014	87	III/IV	18.01	8.7	10 (17 III–7.5 IV)	KPS, RPA, histology, and PTV margin

NR: not reported.